Cargando…
Comment on “Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?”
Autores principales: | Cure, Erkan, Cumhur Cure, Medine, Kucuk, Adem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314659/ https://www.ncbi.nlm.nih.gov/pubmed/32588188 http://dx.doi.org/10.1007/s11481-020-09938-3 |
Ejemplares similares
-
Colchicine may not be effective in COVID-19 infection; it may even be harmful?
por: Cumhur Cure, Medine, et al.
Publicado: (2020) -
Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis
por: Kucuk, Adem, et al.
Publicado: (2020) -
Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)
por: Cure, Erkan, et al.
Publicado: (2020) -
NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection
por: Cumhur Cure, Medine, et al.
Publicado: (2020) -
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
por: Cure, Erkan, et al.
Publicado: (2021)